Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00130728
Status:
COMPLETED
Last Update Posted:
2021-01-14
First Post:
2005-08-12
Brief Title:
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase III Multicenter Placebo-Controlled Double-Blind Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva Erlotinib Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer NSCLC After Failure of Standard First-Line Chemotherapy
Status:
COMPLETED
Status Verified Date:
2020-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase III multicenter placebo-controlled double-blind randomized study Approximately 650 patients will be randomized in a 11 ratio to one of two treatment arms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None